Life Sciences»Pharmaceuticals»Diseases & Conditions»Psoriasis
Lowest Prices Guaranteed | Length | Publisher | Published Date | SKU |
---|---|---|---|---|
from $4,995 | 208 Pages | GlobalData | April, 2016 | GBDT15082060 |
Lowest Prices Guaranteed | |
Price | from $4,995 |
---|---|
Length | 208 Pages |
Publisher | GlobalData |
Published Date | April, 2016 |
SKU | GBDT15082060 |
Psoriasis - India Drug Forecast and Market Analysis to 2024
Summary
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.
GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.
Although India has an estimated psoriasis prevalence of over 2.8%, the market is weak. However, we expect it to grow considerably. We attribute this growth primarily to the growth of biosimilars, expanding patient access, and the introduction of biologics, such as Cosentyx, that are well-established in other developed markets. Although India relies on several therapies to treat patients with psoriasis, biologic therapies are used infrequently due to their high cost.
Scope
Online Download | $4,995 | |
---|---|---|
Site License | $9,990 | |
Global Site License | $14,985 |
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook